Ark Biotech

Executive Summary

Ark Biotech is a San Francisco-based synthetic biology company pioneering high-fidelity bioprocess simulation software. Its platform leverages advanced multiphysics models to create virtual bioreactors, allowing biopharma companies and CDMOs to accelerate process development, optimize manufacturing, and reduce physical experimentation. Founded in 2019, the company aims to democratize computational tools for upstream cell culture across all development stages, from early R&D to commercial scale. By replacing costly and time-consuming trial-and-error experimentation with accurate in silico predictions, Ark Biotech addresses a critical bottleneck in biologics production. The company's technology has the potential to significantly reduce the cost of goods for complex therapeutics, improve scalability, and shorten timelines for life-saving medicines.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Close to Expand Commercialization70% success
• Q1 2027Major Partnership with Top-20 Biopharma or CDMO60% success
• Q4 2026Release of AI-Enhanced Simulation Module50% success